



We Claim:

1. A compound of Formula I:



where:



Ar is or a heterocycle selected from the group consisting of 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-(C₁-C₆ alkyl)indolin-6-yl, benzothien-2-yl, benzothien-5-yl, benzothien-6-yl, 5-(C₁-C₆ alkyl)benzothien-2-yl, 6-(C₁-C₆ alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-(C₁-C₆ alkyl)indol-2-yl;

A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;


R¹ and R² are either both halo, both trifluoromethyl, or one is halo and the other is C₁-C₆ alkyl; or

a pharmaceutically acceptable base addition salt thereof.


2. The compound of claim 1, wherein the compound is a pharmaceutically acceptable base addition salt.

3. The compound of claim 2, wherein the pharmaceutically acceptable base addition salt is a sodium salt.

4. A method of treating susceptible neoplasms in a mammal comprising administering to a mammal in need of such treatment an oncolytically effective amount of a compound of Formula I:



where:




or a heterocycle selected from the group consisting of 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-($\text{C}_1\text{-C}_6$ alkyl)indolin-6-yl, benzothien-2-yl, benzothien-5-yl, benzothien-6-yl, 5-($\text{C}_1\text{-C}_6$ alkyl)benzothien-2-yl, 6-($\text{C}_1\text{-C}_6$ alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-($\text{C}_1\text{-C}_6$ alkyl)indol-2-yl;

A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;


R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is $\text{C}_1\text{-C}_6$ alkyl; or

a pharmaceutically acceptable base addition salt thereof.

5. A pharmaceutical formulation comprising a compound of Formula I:



where:



Ar is or a heterocycle selected from the group consisting of 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-(C₁-C₆ alkyl)indolin-6-yl, benzothien-2-yl, benzothien-5-yl, benzothien-6-yl, 5-(C₁-C₆ alkyl)benzothien-2-yl, 6-(C₁-C₆ alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-(C₁-C₆ alkyl)indol-2-yl;

A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;

R¹ and R² are either both halo, both trifluoromethyl, or one is halo and the other is C₁-C₆ alkyl; or

a pharmaceutically acceptable base addition salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.